outcome: Loss of prognostic utility after several hours. Epilepsia 2009; 50:1566 -1571 " What does not kill you makes you stronger." This quote was previously used to describe investigation of preconditioning, where sublethal exposure to noxious stimuli resulted in a subsequent, more robust cellular response to stress. Ischemia is the best example of this phenomenon. The existence of multiple, diverse preconditioning stimuli that confer protection represents the familiar phenomenon of "cross-tolerance." The purpose of this editorial is not to discuss the possibility of toxicity of inhalational anesthetic agents but to comment on the article "Sevoflurane preconditioning improves mitochondrial function and longterm neurological sequelae after transient cerebral ischemia: Role of mitochondrial permeability transition" by Ye et al (1) in this issue of Critical Care Medicine. This article adds some interesting and new information to the area of preischemic conditioning by volatile anesthetic agents. Such work has been presented in myocardial ischemia research, but the potential mechanism(s) of action and possibility of longer-term protection in brain have not previously been described.
Mitochondria are ubiquitous organelles responsible for many essential cellular processes in eukaryotic organisms and are considered the "gatekeepers of life and death." The major functions of mitochondria include the production of >90% of ATP, the regulation of intracellular calcium, redox signaling, and the regulation of apoptosis. Given the important role of mitochondria in neuronal physiology, it is not surprising that mitochondria actively participate in preconditioning signaling pathways.
What this study shows is the potential involvement of the mitochondria in neuroprotection provided by sevoflurane preconditioning (SPC) delivered for 60 mins at 24 hrs before transient cerebral ischemia in a rodent model. The authors showed that: 1) SPC reduced infarct vol ume at 14 days after reperfusion and improved neurological sequelae up to 6 wks after temporary focal cerebral isch emia; 2) SPC protected mitochondrial function evidenced by preserved respira tory chain complex activities, lowered mitochondrial hydrogen peroxide pro duction, and hyperpolarized mitochondrial membrane potential during early reperfusion; 3) SPC significantly attenu ated mitochondrial permeability transi tion pore (mPTP) opening in this model during early reperfusion, and isolated mitochondria demonstrated reduced sen sitivity to Ca 2+induced mPTP opening after preexposure to sevoflurane in vitro; and 4) The beneficial effects of SPC could be negated by an mPTP opener and mimicked by an agent (cyclosporin A) that reduced mPTP opening.
The mPT is an increase in the permeability of the mitochondrial membranes to molecules with molecular weight <1500 Da. mPT results from the opening of a mitochondrial permeability transition pore, mPTP, that is formed in the inner membrane of the mitochondria under certain pathological conditions such as traumatic brain injury and stroke. Induction of the permeability transition pore can lead to mitochondrial swelling and cell death through apoptosis or necrosis depending on the particular biological setting and therefore is a plausible target for therapeutic intervention.
However, SPC has a limited effect on mitochondrial electron transfer chain II, and if the electron transfer chain process is in "series" this presents a very serious limitation to SPC. The authors investigated the differential effects of SPC on electron transfer chain complex II activity and other complex (I, III, IV) activities. The authors reported that the data are stable (response to reviewer's comments), having repeated this experiment several times with consistent results showing that SPC does not affect electron transfer chain complex II activity.
Complex II (succinate dehydrogenase) binds to the inner mitochondrial membrane. Despite minimal effects on complex II, SPC promoted complex I, III, and IV activities, and, importantly, preserved the general mitochondrial function (mitochondrial membrane potential) and reduced mitochondrial reactive oxygen species production. But why does SPC fail to affect complex II activity? The authors candidly responded to reviewers, "as translational scientists, frankly speaking, we currently have no answer. But we infer this may be related to the mPTP inhibition, because CsA also increases complex I, III, and IV activities, but not complex II (unpublished data)." Fascinatingly, it has been shown that ischemic preconditioning increases the activity of mitochondrial respiratory chain complexes I, III, and IV in synaptosomes isolated from rat hippocampus (2, 3).
More importantly, these changes are associated with improved longer-term histological and neurological outcome after cerebral ischemia. The importance of determining whether a neuroprotective strategy can improve long-term neurological outcome in animal studies is a key recommendation of the Stroke Therapy Academic Industry Roundtable. Stroke Therapy Academic Industry Roundtable strongly recommends that "Histological and behavioral studies need to include studies conducted at least 2 to 3 wks or longer after stroke onset to demonstrate a sustained benefit "What does not kill you makes you stronger"* with emphasis on behavioral outcomes in delayed survival studies (4, 5 A uthors of science fiction have been writing for decades about the use of machines to heal disease and injury, where patients are placed in tanks and plumbed with a variety of devices to keep them alive and accelerate recovery. Modern-day clinicians reveal comparable ambitions in their descriptions of such systems as multiple organ system extracorporeal support (1) and total extracorporeal organ support (2). Are we really there yet? Not quite. Current technology can be used to overcome cardiac and renal failure for months to years, and respiratory failure for weeks to months, but effective extracorporeal support of other organs has proven more elusive.
One of the problems with contemporary extracorporeal technology is keeping track of the ever-changing circuit configurations and components. Even traditional terms can be confusing, with a label such as extracorporeal life support being variably applied as an umbrella term for either extracorporeal membrane oxygenation (ECMO) or ventricular assist device, as a term specific to the function of the blood pump in venoarterial ECMO, or as a generic term for any device that siphons blood outside the patient in order to support a given organ. Evolving technology needs clear terminology and consistent usage. Systems should be classified by their intended function (see Table 1 ). For example, in peripheral venoarterial ECMO, the oxygenator clears carbon dioxide and provides a variable degree of systemic oxygenation (partially depending on the location of the return cannula and the force of ventricular ejection) (3, 4), but the whole circuit is intended primarily for use as mechanical circulatory support and should be classified as such. Until the sidereal ambitions of total extracorporeal organ support are truly realized, the term advanced extracorporeal life support could be used for techniques that are capable of completely replacing the primary functions of at least two organs. Newer devices that provide both extracorporeal carbon dioxide removal and continuous renal replacement therapy (CRRT) (e.g., Decapsmart, Medica, Modena, Italy) (5) would not be considered as advanced extracorporeal life support because, useful though they may prove in other circumstances, they cannot save the patient with total lung failure. Extracorporeal liver support is not included in this taxonomy because its efficacy is not well established (6).
Is this classification really necessary? There are several reasons why it is worthwhile considering. First, nomenclature becomes clearer if it is based on what pathophysiological problem the system is intended to address, rather than what it might be capable of under different circumstances or with alternative configurations. Second, it emphasizes exactly what modern technology is capable of doing and what it is not. For example, extracorporeal support is at best only partially effective in patients with advanced liver failure (6-8). Whether this will change with the advent of new bioartificial devices remains to be seen (9), but current technology cannot match the detoxification capabilities of the liver. All extracorporeal systems have potential hazards, and it is important we are not too hasty in laying claims for new technology without adequate assessment of both safety and efficacy. Third, multiple extracorporeal systems interact with each other, and the intended function of one may interfere with the others.
In this issue of Critical Care Medicine, Dr. Selewski and colleagues (10) report a series of critically ill children supported with advanced extracorporeal life support, specifically ECMO and CRRT. Many of the patients had congenital heart disease and were in the neonatal age range, a population known to have worse outcomes with CRRT than older children (11). The authors found that the degree of fluid overload at initiation of CRRT was associated with worse outcome. What are the possible explanations for these results? Perhaps fluid overload is simply and inherently bad for patients. Comparable findings have been demonstrated in other patient populations, both adult and pediatric, but not in ECMO patients (12) (13) (14) . A second possibility is that fluid overload is just a marker of severity of illness, with sicker patients perhaps having more capillary leak, hypoalbuminemia, bleeding, and other problems that fuel aggressive fluid resuscitation (11). The observation that outcomes in the current study were unaffected by correcting fluid overload might support this theory.
If fluid overload is intrinsically bad then the clinical implications of this study are obvious: start CRRT early and do not allow patients to become fluid overloaded.
